This is a working overview of Alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
=== Vertebrates === In birds, the trachea runs from the pharynx to the syrinx, from which the primary bronchi diverge. Swans have an unusually elongated trachea, part of which is coiled beneath the sternum; this may act as a resonator to amplify sound. In some birds, the tracheal rings are complete, and may even be ossified. In amphibians, the trachea is normally extremely short, and leads directly into the lungs, without clear primary bronchi. A longer trachea is, however, found in some long-necked salamanders, and in caecilians. While there are irregular cartilagenous nodules on the amphibian trachea, these do not form the rings found in amniotes. The only vertebrates to have lungs, but no trachea, are the lungfish and the Polypterus, in which the lungs arise directly from the pharynx.
This can be used as the basis for biosensors. Once assembled, the two separate DNA strands can be ligated into a single strand. Unmodified aptamers are cleared rapidly from the bloodstream, with a half-life of seconds to hours. This is mainly due to nuclease degradation, which physically destroys the aptamers, as well as clearance by the kidneys, a result of the aptamer's low molecular weight and size. Several modifications, such as 2'-fluorine-substituted pyrimidines and polyethylene glycol (PEG) linkage, permit a serum half-life of days to weeks. PEGylation can add sufficient mass and size to prevent clearance by the kidneys in vivo. Unmodified aptamers can treat coagulation disorders. The problem of clearance and nuclease digestion is diminished when they are applied to the eye, where there is a lower concentration of nuclease and the rate of clearance is lower. Rapid clearance from serum can also be useful in some applications, such as in vivo diagnostic imaging. In a study on aptamers designed to bind with proteins associated with Ebola infection, a comparison was made among three aptamers isolated for their ability to bind the target protein EBOV sGP. Although these aptamers vary in both sequence and structure, they exhibit remarkably similar relative affinities for sGP from EBOV and SUDV, as well as EBOV GP1.2. Notably, these aptamers demonstrated a high degree of specificity for the GP gene products.
==== Arrhenoblastoma ==== Arrhenoblastoma is an uncommon tumor of the ovary. It is composed of sterol cells, Leydig cells, or some combination of the two. The tumor can produce male or female hormones and may cause masculinization. In a prepubescent child, a tumor may cause precocious puberty. Malignant arrhenoblastoma accounts for 30% of cases of arrhenoblastoma, the other 70% being largely benign and curable with surgery.
Works by Marguerite Yourcenar at Open Library Petri Liukkonen. "Marguerite Yourcenar". Books and Writers. Stockinger, Jacob (3 March 2004) [2002]. "Yourcenar, Marguerite (1903–1987)". In Summers, Claude J. (ed.). glbtq: An encyclopedia of gay, lesbian, bisexual, transgender, and queer culture. Chicago: glbtq, Inc. Archived from the original on 16 January 2009. Marguerite Yourcenar et Suzanne Lilar : plus qu’une rencontre, une complicité by Michèle Goslar English translations of Marguerite Yourcenar by Walter Jacob Kaiser, Catalogue of correspondence and manuscripts concerning Walter Kaiser's English translation of works by French writer Marguerite Yourcenar, Houghton Library, Harvard University Accueil
Additionally, the regulation of sulfur plays an interconnected role with other nutrient cycles like carbon, nitrogen, and iron. For example, if MetR is impaired, the management of iron homeostasis is at risk. In plants, under sulfur-limiting conditions they optimize nitrogen assimilation to maintain metabolic homeostasis. In animals, since sulfur uptake is primarily obtained through the diet in the form of cysteine or methionine, the regulation of sulfur metabolism is done via the transsulfuration pathway. In this pathway, methionine is converted to homocysteine and then later converted to cysteine via the enzymes Cystathionine Beta-synthase (CBS) and Cystathionine gamma-lyase (CGL). Cysteine is utilized for glutathione production, and high levels of glutathione feedback negatively to downregulate the enzymes CBS and CGL. Regulation of sulfur assimilation is tightly controlled to ensure balanced production of sulfur-compounds like cysteine, methionine, and glutathione. These are key molecules that play a role in redox balance, and protein synthesis. Sulfur levels are also interconnected with other nutrient cycles to maintain an overall metabolic balance in plants, animals, and fungi.
Sources: en.wikipedia.org
In addition, one case of mildly elevated liver enzymes (1 of 14; 7%), possibly related to bicalutamide, was observed but resolved spontaneously without discontinuation of therapy. Additional research is necessary to more clearly determine the true effectiveness and safety of bicalutamide and anastrozole in the treatment of FMPP. No long-term results for the BATT study have been published as of yet, but a 5-year follow-up of two of the boys in the study was published and reported continued effectiveness. It is intended that the study will continue until all of the boys reach adult final height, with an additional publication planned in the future. In addition to the BATT study, a variety of case reports and series of bicalutamide in combination with an aromatase inhibitor in male peripheral precocious puberty have been published. These case reports have described similar results as those of the BATT study. Alternatives to bicalutamide in the treatment of male peripheral precocious puberty include spironolactone, cyproterone acetate, and ketoconazole. Bicalutamide with anastrozole is considered to be superior to the combination of spironolactone and testolactone in peripheral precocious puberty, with greater efficacy and fewer side effects. This corresponds to the fact that bicalutamide is a much more potent and selective antiandrogen than spironolactone. Additionally, dosing is easier with bicalutamide, as it requires administration only once daily as opposed to twice daily at 12-hour intervals with spironolactone.
=== Retail sale of sauces === In the spring of 2020, Chick-fil-A test-trialed the sale of two of their dipping sauces at some supermarkets in Florida, with all profits earmarked for a scholarship fund for the company's store-level employees. The trial was considered successful, and distribution was expanded nationwide by 2021. Two more sauces were added in 2023. In October 2022, the company trialed expansion of the program to include its salad dressings in the Cincinnati metropolitan area and in parts of Tennessee, and expanded nationwide in spring 2023. In January 2025, Chick-fil-A announced plans to centralize its lemonade production by moving it from its restaurant locations to a single, automated facility in Santa Clarita, California. This new plant is capable of processing between 30 and 35 truckloads of lemons daily, with each truckload containing 50,000 pounds of lemons.
Dent, London, 1981) ISBN 978-0-460-04535-3 Is Life an Astronomical Phenomenon? (University College Cardiff Press, 1982) ISBN 9780906449493 Why Neo-Darwinism Does Not Work (with Fred Hoyle) (University College Cardiff Press, 1982) ISBN 9780906449509 Proofs that Life is Cosmic (with Fred Hoyle) (Institute of Fundamental Studies, Sri Lanka, Memoirs no.1, 1982) From Grains to Bacteria (with Fred Hoyle) (University College Cardiff Press, 1984) ISBN 9780906449646 Fundamental Studies and the Future of Science (ed.) (University College Cardiff Press, 1984) ISBN 9780906449578 Living Comets (with Fred Hoyle) (University College Cardiff Press, 1985) ISBN 9780906449790 Archaeopteryx, the Primordial Bird: A Case of Fossil Forgery (with Fred Hoyle) (Christopher Davies, Swansea, 1986) ISBN 9780715406656 The Theory of Cosmic Grains (with Fred Hoyle) (Kluwer, Dordrecht, 1991) ISBN 9780792311898 Life on Mars? The Case for a Cosmic Heritage (with Fred Hoyle) (Clinical Press, Bristol, 1997) ISBN 9781854570413 Astronomical Origins of Life: Steps towards Panspermia (with Fred Hoyle) (Kluwer, Dordrecht, 2000) ISBN 9780792360810 Cosmic Dragons: Life and Death on Our Planet (Souvenir Press, London, 2001) ISBN 9780285636064 Fred Hoyle's Universe (ed. with G. Burbidge and J. Narlikar) (Kluwer, Dordrecht, 2003) ISBN 9781402014154 A Journey with Fred Hoyle (World Scientific, Singapore, 2005) ISBN 9789812565792 Comets and the Origin of Life (with J. Wickramasinghe and W.
=== Retrial === At a hearing on 25 September 2023, the Crown Prosecution Service confirmed that there would be a retrial on one of the six attempted‑murder counts on which the original jury had been unable to reach a verdict. The retrial was scheduled to take place after the Court of Appeal had considered whether Letby would be granted permission to appeal her existing convictions. The retrial began on 10 June 2024. On 2 July, Letby was found guilty of attempted murder, and on 5 July she received a further whole‑life order. On 24 October 2024, Letby applied for permission to appeal this conviction, arguing that prejudicial media coverage should have prevented the trial from proceeding. The Court of Appeal rejected the application.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.